Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces US Food and Drug Administration (FDA) clearance of the Group’s Investigational New Drug (IND) application for AT247, the Group’s proprietary wholly owned ultra-rapid insulin for the treatment of diabetes.
Arecor Therapeutics Plc
Advancing today's therapies to enable healthier lives.
Telephone: +44 (0)1223 426 060
Chesterford Research Park Little Chesterford Saffron Walden
Post Code: CB10 1XL
Country: United Kingdom
Membership Type: Corporate 21-50